<p>美国合众银行减少了对 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）股票的持股比例，下降了 16.7%，根据其最近向 SEC 提交的 13F 文件。该公司在此期间出售了 7,176 股后，持有 35,705 股生物技术公司的股票。截至其最近向 SEC 提交的文件，美国合众银行在 Exelixis 的持股价值为 1,574,000 美元。</p>
<ul>
<li>如果有的话，3 只适合购买的股票以应对软着陆</li>
</ul>
<p>其他对冲基金最近也买卖了该公司的股票。Byrne Asset Management LLC 在第二季度将其在 Exelixis 的持股比例提高了 129.0%。Byrne Asset Management LLC 现在拥有 710 股生物技术公司的股票，价值 31,000 美元，此前在此期间又购买了 400 股。Family Legacy Financial Solutions LLC 在第二季度获得了 Exelixis 的新股份，价值约 33,000 美元。Hemington Wealth Management 在第一季度将其在 Exelixis 的持股比例提高了 211.3%。Hemington Wealth Management 现在拥有 769 股生物技术公司的股票，价值 28,000 美元，此前在此期间又购买了 522 股。Bartlett &amp; CO. Wealth Management LLC 在第一季度获得了 Exelixis 的新股份，价值约 37,000 美元。最后，Steph &amp; Co.在第二季度获得了 Exelixis 的新股份，价值约 44,000 美元。目前 85.27% 的股票由机构投资者和对冲基金持有。</p>
<h2>Exelixis 股价下跌 2.0%</h2>
<p>EXEL 的股票在周五开盘价为 39.21 美元。该公司的市值为 105.6 亿美元，市盈率为 18.85，PEG 比率为 0.80，贝塔值为 0.38。Exelixis, Inc.的 1 年最低价为 27.86 美元，1 年最高价为 49.62 美元。该公司的 50 日简单移动平均线为 38.79 美元，200 日简单移动平均线为 39.98 美元。</p>
<ul>
<li>3 只强劲的生物技术股票值得关注，随着行业接近突破</li>
</ul>
<p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近在 7 月 28 日（星期一）发布了其财报。该生物技术公司报告本季度每股收益为 0.75 美元，超出分析师一致预期的 0.63 美元，超出 0.12 美元。该季度的收入为 5.6826 亿美元，而一致预期为 5.7436 亿美元。Exelixis 的净利润率为 27.01%，股本回报率为 27.47%。该公司的季度收入同比下降了 10.8%。在去年同期，该公司每股收益为 0.84 美元。Exelixis 已设定其 2025 财年的每股收益指导。作为一个整体，研究分析师预测 Exelixis, Inc.今年将发布每股收益 2.04 美元。</p>
<h2>华尔街分析师的看法</h2>
<p>几家券商对 EXEL 发表了评论。Weiss Ratings 在 10 月 8 日（星期三）的一份报告中重申了对 Exelixis 股票的 “买入（b）” 评级。Wall Street Zen 在 10 月 3 日（星期五）的一份报告中将 Exelixis 的股票评级从 “持有” 上调至 “买入”。Guggenheim 在 7 月 29 日（星期二）重申了 “买入” 评级，并对 Exelixis 的股票设定了 45.00 美元的目标价。巴克莱在 9 月 17 日（星期三）开始覆盖 Exelixis 的股票。他们对该股票给予了 “持平” 评级，并设定了 40.00 美元的目标价。最后，Stephens 在 6 月 24 日（星期二）将 Exelixis 的股票评级从 “持平” 上调至 “超配”，并将该公司的目标价从 29.00 美元提高至 60.00 美元。十五位研究分析师对该股票给予了买入评级，九位分析师对该公司的股票给予了持有评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 44.42 美元。</p>
<ul>
<li>现在投资的 7 只最佳癌症股票</li>
</ul>
<p><strong>查看我们关于 Exelixis 的最新股票报告</strong></p>
<h2>关于 Exelixis</h2>
<p>（免费报告）</p>
<p>Exelixis, Inc.是一家肿瘤学公司，专注于在美国发现、开发和商业化用于治疗难治性癌症的新药物。该公司提供 CABOMETYX 片剂，用于治疗接受过抗血管生成治疗的晚期肾细胞癌患者；以及 COMETRIQ 胶囊，用于治疗进展性和转移性髓样甲状腺癌。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Exelixis 更好</li>
<li>如何利用高贝塔股票最大化投资利润</li>
<li>Salesforce 期待已久的拐点来了：继续上涨！</li>
<li>关于 Markup 计算器</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候购买了吗？</li>
<li>超买股票解释：你应该交易它们吗？</li>
<li>Archer 以战略举措收购竞争对手的专利宝藏</li>
</ul>
<p><strong>想看看其他对冲基金持有 EXEL 的情况吗？</strong> 访问 HoldingsChannel.com，获取 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
<p>在考虑 Exelixis 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Exelixis 并不在名单上。</p>
<p>虽然 Exelixis 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

伊克力西斯

美国合众银行

<p>美国合众银行（US Bancorp）已将其在伊克力西斯（Exelixis, Inc.，NASDAQ:EXEL）的持股减少了 16.7%，目前持有 35,705 股，价值 157 万美元。其他对冲基金也调整了他们的持仓，其中 Byrne Asset Management 等公司的持股显著增加。伊克力西斯的股票开盘价为 39.21 美元，市值为 105.6 亿美元。该公司报告每股收益为 0.75 美元，超出预期，尽管同比收入有所下降。分析师对该股票维持 “适度买入” 评级，普遍目标价为 44.42 美元</p>

<p>US Bancorp DE reduced its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 16.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 35,705 shares of the biotechnology company's stock after selling 7,176 shares during the period. US Bancorp DE's holdings in Exelixis were worth $1,574,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>美国合众银行减少了对 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）股票的持股比例，下降了 16.7%，根据其最近向 SEC 提交的 13F 文件。该公司在此期间出售了 7,176 股后，持有 35,705 股生物技术公司的股票。截至其最近向 SEC 提交的文件，美国合众银行在 Exelixis 的持股价值为 1,574,000 美元。</p>
</div><ul>
<li>3 Stocks to Buy for a Soft Landing, If There Is One</li>
</ul>
<div class="lb-trans"><ul>
<li>如果有的话，3 只适合购买的股票以应对软着陆</li>
</ul>
</div><p>Other hedge funds have also recently bought and sold shares of the company. Byrne Asset Management LLC raised its holdings in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after buying an additional 400 shares during the period. Family Legacy Financial Solutions LLC acquired a new stake in Exelixis during the 2nd quarter worth approximately $33,000. Hemington Wealth Management raised its holdings in Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock worth $28,000 after buying an additional 522 shares during the period. Bartlett &amp; CO. Wealth Management LLC acquired a new stake in Exelixis during the 1st quarter worth approximately $37,000. Finally, Steph &amp; Co. acquired a new stake in Exelixis during the 2nd quarter worth approximately $44,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金最近也买卖了该公司的股票。Byrne Asset Management LLC 在第二季度将其在 Exelixis 的持股比例提高了 129.0%。Byrne Asset Management LLC 现在拥有 710 股生物技术公司的股票，价值 31,000 美元，此前在此期间又购买了 400 股。Family Legacy Financial Solutions LLC 在第二季度获得了 Exelixis 的新股份，价值约 33,000 美元。Hemington Wealth Management 在第一季度将其在 Exelixis 的持股比例提高了 211.3%。Hemington Wealth Management 现在拥有 769 股生物技术公司的股票，价值 28,000 美元，此前在此期间又购买了 522 股。Bartlett &amp; CO. Wealth Management LLC 在第一季度获得了 Exelixis 的新股份，价值约 37,000 美元。最后，Steph &amp; Co.在第二季度获得了 Exelixis 的新股份，价值约 44,000 美元。目前 85.27% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Exelixis Trading Down 2.0%</h2>
<div class="lb-trans"><h2>Exelixis 股价下跌 2.0%</h2>
</div><p>Shares of EXEL opened at $39.21 on Friday. The company has a market cap of $10.56 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 0.80 and a beta of 0.38. Exelixis, Inc. has a 1-year low of $27.86 and a 1-year high of $49.62. The company's fifty day simple moving average is $38.79 and its 200 day simple moving average is $39.98.</p>
<div class="lb-trans"><p>EXEL 的股票在周五开盘价为 39.21 美元。该公司的市值为 105.6 亿美元，市盈率为 18.85，PEG 比率为 0.80，贝塔值为 0.38。Exelixis, Inc.的 1 年最低价为 27.86 美元，1 年最高价为 49.62 美元。该公司的 50 日简单移动平均线为 38.79 美元，200 日简单移动平均线为 39.98 美元。</p>
</div><ul>
<li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲的生物技术股票值得关注，随着行业接近突破</li>
</ul>
</div><p>Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm's revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.</p>
<div class="lb-trans"><p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近在 7 月 28 日（星期一）发布了其财报。该生物技术公司报告本季度每股收益为 0.75 美元，超出分析师一致预期的 0.63 美元，超出 0.12 美元。该季度的收入为 5.6826 亿美元，而一致预期为 5.7436 亿美元。Exelixis 的净利润率为 27.01%，股本回报率为 27.47%。该公司的季度收入同比下降了 10.8%。在去年同期，该公司每股收益为 0.84 美元。Exelixis 已设定其 2025 财年的每股收益指导。作为一个整体，研究分析师预测 Exelixis, Inc.今年将发布每股收益 2.04 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>Several brokerages have commented on EXEL. Weiss Ratings restated a &#34;buy (b)&#34; rating on shares of Exelixis in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Exelixis from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Friday, October 3rd. Guggenheim reiterated a &#34;buy&#34; rating and issued a $45.00 price objective on shares of Exelixis in a report on Tuesday, July 29th. Barclays assumed coverage on shares of Exelixis in a report on Wednesday, September 17th. They issued an &#34;equal weight&#34; rating and a $40.00 price objective on the stock. Finally, Stephens upgraded shares of Exelixis from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and lifted their price objective for the company from $29.00 to $60.00 in a report on Tuesday, June 24th. Fifteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $44.42.</p>
<div class="lb-trans"><p>几家券商对 EXEL 发表了评论。Weiss Ratings 在 10 月 8 日（星期三）的一份报告中重申了对 Exelixis 股票的 “买入（b）” 评级。Wall Street Zen 在 10 月 3 日（星期五）的一份报告中将 Exelixis 的股票评级从 “持有” 上调至 “买入”。Guggenheim 在 7 月 29 日（星期二）重申了 “买入” 评级，并对 Exelixis 的股票设定了 45.00 美元的目标价。巴克莱在 9 月 17 日（星期三）开始覆盖 Exelixis 的股票。他们对该股票给予了 “持平” 评级，并设定了 40.00 美元的目标价。最后，Stephens 在 6 月 24 日（星期二）将 Exelixis 的股票评级从 “持平” 上调至 “超配”，并将该公司的目标价从 29.00 美元提高至 60.00 美元。十五位研究分析师对该股票给予了买入评级，九位分析师对该公司的股票给予了持有评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 44.42 美元。</p>
</div><ul>
<li>7 Best Cancer Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在投资的 7 只最佳癌症股票</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on Exelixis</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Exelixis 的最新股票报告</strong></p>
</div><h2>About Exelixis</h2>
<div class="lb-trans"><h2>关于 Exelixis</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.</p>
<div class="lb-trans"><p>Exelixis, Inc.是一家肿瘤学公司，专注于在美国发现、开发和商业化用于治疗难治性癌症的新药物。该公司提供 CABOMETYX 片剂，用于治疗接受过抗血管生成治疗的晚期肾细胞癌患者；以及 COMETRIQ 胶囊，用于治疗进展性和转移性髓样甲状腺癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Exelixis</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>About the Markup Calculator</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>Overbought Stocks Explained: Should You Trade Them?</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Exelixis 更好</li>
<li>如何利用高贝塔股票最大化投资利润</li>
<li>Salesforce 期待已久的拐点来了：继续上涨！</li>
<li>关于 Markup 计算器</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候购买了吗？</li>
<li>超买股票解释：你应该交易它们吗？</li>
<li>Archer 以战略举措收购竞争对手的专利宝藏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding EXEL?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 EXEL 的情况吗？</strong> 访问 HoldingsChannel.com，获取 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EXEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Exelixis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
</div><p>Before you consider Exelixis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Exelixis 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Exelixis 并不在名单上。</p>
</div><p>While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Exelixis 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

美国合众银行 DE 在 Exelixis 公司持有 157 万美元的股票头寸